Saturday, August 06, 2011
conference notice: Welcome to the 12th International Congress of Human Genetics annual meeting (Montreal)
On behalf of The American Society of Human Genetics (ASHG) and the International Federation of Human Genetics Societies (IFHGS), it gives us great pleasure to invite human geneticists from all around the world to attend and participate in the 12th International Congress of Human Genetics (ICHG) and the 61st ASHG Annual Meeting. The Congress will be held at the Le Palais des Congrès (Convention Center) in Montreal (Quebec), Canada from Tuesday, October 11th through Saturday, October 15th 2011, coinciding with the ASHG meeting.
The ICHG is the foremost meeting of the world human genetics community and is held every five years. The first Congress was held in 1956 in Copenhagen and subsequent venues have included Berlin, Washington, DC, Rio de Janeiro, Vienna and most recently Brisbane. The anticipated attendance is 7,000 delegates from over 60 countries around the world.
National Patient Safety Foundation: ASPPS - info/membership (fee based membership)
Membership in the American Society of Professionals in Patient Safety is open to professionals whose primary responsibility is patient safety, as well as to individuals across other healthcare disciplines, medical students, providers, risk managment and quality leaders, patient safety advocates and all those committed to safe patient care. Individual membership is the newest addition to NPSF’s portfolio, which includes continuing education credits through the Professional Learning Series, the NPSF Annual Patient Safety Congress, and other high-value programs. S
Friday, August 05, 2011
Thursday, August 04, 2011
Cancer Genome Atlas (press release July 2011) TCGA Completes Ovarian Cancer (serous) Analysis - TCGA plus link to video discussion
To view a video of Dr. Spellman discussing TCGA and the ovarian cancer findings, please go to http://www.youtube.com/watch?v=TK_CIGEUHxU
Wednesday, August 03, 2011
Bionomics - News - new trials phase 1/11 announced - BNC105 (combo)
Ovarian cancer trial planned:
- Randomised Phase I/II trial of BNC105 in combination with carboplatin and gemcitabine
- Preclinical data support use of BNC105 in combination with platinum (cisplatin; carboplatin) based therapeutic regimens
Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer
Note: in research/technical
Abstract
"In ovarian cancer, the immune system fails to eradicate established tumors partly due to the induction of immune tolerance within tumor microenvironment.....cont'd
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes
"Overall, the data suggest that genomic variation at multiple loci that encode proteins that interact biologically with BRCA1 are associated with modified breast cancer and ovarian cancer risk in women who carry BRCA1 mutations."
Use of SAND Balloon Catheter for Laparoscopic Management of Extremely Large Ovarian Cysts (intraperitoneal spillage)
"With proper patient selection, the SAND balloon catheter can be extremely useful in laparoscopic removal of very large adnexal masses, without intraperitoneal spillage."
Use of metformin and the risk of ovarian cancer: A case-control analysis
OBJECTIVE:
To explore the association between use of metformin or other antidiabetic drugs and the risk of ovarian cancer.CONCLUSION:
In this large epidemiological study long-term use of metformin, but not of sulfonylureas, was associated with a tendency towards a decreased risk of ovarian cancer. Long-term use of insulin was associated with an increased risk of ovarian cancer.Sunday, July 31, 2011
Saturday, July 30, 2011
(recap-dated July 29, 2011) Gynecologic Cancers Update from the 2011 Annual Oncology Meeting « OncoFacts
Gynecologic Cancers Update from the 2011 Annual Oncology Meeting
Reviewed by Bradley Monk, MD, FACS, FACOG
abstract - European Journal of Obstetrics & Gynecology and Reproductive Biology : Ovarian cancer risk assessment: a tool for preoperative assessment
DIA Patient Organization/ Advocate Track - Drug Information Association - conference notice Rare Diseases/Orphan Products Oct 11-13th Washington, Dc
Patient Organization/ Advocate Track | ||||||||
| ||||||||
ELC : Interactive Case: Ovarian Cancer: Symptomatic Stage IV Disease Dr Thomas Herzo
Note: requires registration (free)
Interactive Case: Ovarian Cancer: Symptomatic Stage IV Disease Dr Thomas Herzog presents a provocative discussion focusing on options for treatment of a patient presenting with stage IV disease. His discussion incorporates the contemporary option of neo-adjuvant chemotherapy as well as the addition of an anti-angiogenic agent into the initial treatment regimen.FDA Warns of Serious Drug Interactions in Patients Taking Psychiatric Drugs « news@JAMA (Linezolid/Zyvox/Methylene blue)
"Patients taking certain psychiatric drugs may experience serious neurological problems if they are given the antibacterial medication linezolid (sold under the brand name Zyvox) or methylene blue, a drug that is also used as a dye in some diagnostic procedures and for certain other uses, such as treating cyanide poisoning, according to a pair of warnings issued yesterday by the US Food and Drug Administration (FDA)."
Wiki Methylene blue resource:
http://en.wikipedia.org/wiki/Methylene_blue
Friday, July 29, 2011
Breast density 'linked to specific types of breast cancer' | International Federation of Gynecology and Obstetrics
"Given that the magnitude of the association with breast density is strong across all breast cancer subtypes and particularly for [oestrogen receptor]-negative disease, breast density should be included in risk prediction models across tumour subtypes," the researchers said.
Thursday, July 28, 2011
Cancer Causes and Control - Dietary calcium and magnesium intake in relation to cancer incidence and mortality in a German prospective cohort
"This prospective cohort study provides no strong evidence to support that high dietary calcium and magnesium intake in the intake range observed in a German population may reduce cancer incidence or mortality."
Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial : The Lancet Oncology
Background
Dignity therapy is a unique, individualised, short-term psychotherapy that was developed for patients (and their families) living with life-threatening or life-limiting illness. We investigated whether dignity therapy could mitigate distress or bolster the experience in patients nearing the end of their lives.
abstract: Quantity, Design, and Scope of the Palliative Oncology Literature
"...Comparing 2004 with 2009, we found an increase in the proportion of original studies among all palliative oncology publications but no significant difference in study design or research topic. We identified significant deficiencies in the quantity, design, and scope of the palliative oncology literature...."
abstract: Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
Markman M.
Source
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA.
Abstract
Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined.
abstract - Ovarian cancer risk assessment (OCRA): a tool for preoperative assessment
Objectives
The objective of this pilot study was to determine if the combination of CA 125, menopausal status and prealbumin can be used to accurately predict ovarian cancer in women with pelvic masses.Highlights
► Correct pre-operative diagnosis of ovarian cancer is key to referral.
► Surgery by gynecologic oncologist helps survival.
► Combination of age, prealbumin, CA 125 helps proper referral.
abstract: Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Conclusion: Secondary somatic mutations that restore BRCA1/2 in carcinomas from women with germline BRCA1/2 mutations predict resistance to platinum chemotherapy and may also predict resistance to PARP inhibitors. These mutations were detectable only in ovarian carcinomas of women whom have had previous chemotherapy, either for ovarian or breast carcinoma.
Wednesday, July 27, 2011
Pink makes women donate less to breast-cancer causes: study (ovarian) - media
From The Globe and Mail:
Pink makes women donate less to breast-cancer causes: study
Via The Globe and Mail's iPhone app
Pink makes women donate less to breast-cancer causes: study
Via The Globe and Mail's iPhone app
Sent from my iPhone
McGuinty says loss of Ontario health records very serious issue - The Globe and Mail
From The Globe and Mail:
McGuinty says loss of Ontario health records very serious issue
Via The Globe and Mail's iPhone app
McGuinty says loss of Ontario health records very serious issue
Via The Globe and Mail's iPhone app
Sent from my iPhone
Contemporary Approaches in Targeting Angiogenesis | prIME Oncology
Topics
- Module One: Concepts in Angiogenesis Inhibition
- Module Two: Biomarkers in Angiogenesis
- Module Three: Optimizing Outcomes with Antiangiogenic Therapy in Non-Small Cell Lung Cancer
- Module Four: Optimizing Outcomes with Antiangiogenic Therapy in Colorectal Cancer
- Module Five: Optimizing Outcomes with Antiangiogenic Therapy in Glioblastoma
- Module Six: Practical Considerations in Patient Management Involving Antiangiogenic Therapy
Tuesday, July 26, 2011
Frank words about breast screening - Open Medicine - Analysis and Comment
"......As recently observed in the New England Journal of Medicine, we should “work to prevent vested interests from being granted the loudest voices in health care.”2 The vested interests in what has been termed “the mammography wars”2 are clearly those in the imaging industry, those involved directly in screening programs, and even those in the not-for-profit sector, whose fundraising capacity is enhanced by a public committed to fighting breast cancer.
It is reasonable for women to choose to be screened, but only if they are completely informed about the probability of benefit versus the probability of harm. For 2000 women aged 40–49 who undergo screening for 10 years, the benefit is much smaller in terms of avoiding death from breast cancer than is the harm arising from over-diagnosis and unnecessary treatment for breast cancer, to say nothing of the increased rates of mastectomy associated with screening.22,23 These issues are not widely known to the general public. After over 20 years of involvement in the screening controversy I can only conclude that this is information few want to hear and many want to suppress."
CDC Home Healthcare-associated Infections (HAIs) checklist
Infection Prevention Guide
Guide to Infection Prevention for Outpatient Settings: Minimum Expectations for Safe Care
This summary guide of infection prevention recommendations for outpatient (ambulatory care) settings.
Infection Prevention Checklist
The Infection Prevention Checklist for Outpatient Settings: Minimum Expectations for Safe Care is a companion to the Guide to Infection Prevention for Outpatient Settings: Minimum Expectations for Safe Care.
Monday, July 25, 2011
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians - journal Cancer 2011 - abstract
CONCLUSION:
Physicians reported that they would refer many average-risk women and would not refer many high-risk women for genetic counseling/testing. Intervention efforts, including promotion of accurate risk assessment, are needed.Saturday, July 23, 2011
Fwd: My doctor threatened to fire me for going to a walk-in clinic. Why? - The Globe and Mail
Sent from my iPhone
Begin forwarded message:
From: Sandi Pniauskas <sandipn@sympatico.ca>
Date: 23 July, 2011 7:06:58 AM EDT
To: Sandi Pniauskas <sandipn@sympatico.ca>
Subject: My doctor threatened to fire me for going to a walk-in clinic. Why? - The Globe and Mail
From The Globe and Mail:
My doctor threatened to fire me for going to a walk-in clinic. Why?
Via The Globe and Mail's iPhone app
Sent from my iPhone
Friday, July 22, 2011
Glossary | The Cochrane Collaboration (worth bookmarking)
- examples:
- Adverse effect search for term
- An adverse event for which the causal relation between the drug/intervention and the event is at least a reasonable possibility. The term ‘adverse effect’ applies to all interventions, while ‘adverse drug reaction’ (ADR) is used only with drugs. In the case of drugs an adverse effect tends to be seen from the point of view of the drug and an adverse reaction is seen from the point of view of the patient. Also called: Adverse reaction
- Baseline characteristics search for term
- Values of demographic, clinical and other variables collected for each participant at the beginning of a trial, before the intervention is administered.
- Causal effect search for term
- An association between two characteristics that can be demonstrated to be due to cause and effect, i.e. a change in one causes the change in the other. Causality can be demonstrated by experimental studies such as controlled trials (for example, that an experimental intervention causes a reduction in mortality). However, causality can often not be determined from an observational study.
Molecular Test Aids in Identifying Cancers of Unknown Origin - Medscape (pathology/molecular diagnostic test - 15 different cancer types...)
".....The identity of most tumors can be determined "with confidence" by clinicians with histologic, clinical, and radiographic findings, say the study authors, led by James P. Grenert, MD, from the Department of Pathology at UCSF. "However, when tumors are poorly differentiated or metastatic with no clear primary, identifying the tissue of origin is difficult," they write.
Immunohistochemical stains may or may not be helpful in identifying the tumor origin. Molecular testing of tumors is an additional means of characterizing these tumors, the authors say.
TOO is the only molecular diagnostic test for cancer tissue of origin cleared by the US Food and Drug Association, the manufacturer notes. It is limited to identifying 15 types of tumor tissues: bladder, breast, colorectal, gastric, testicular germ cell, kidney, hepatocellular, nonsmall-cell lung, non-Hodgkin's lymphoma, melanoma, ovarian, pancreas, prostate, thyroid, and sarcoma. These 15 tumor types represent 90% of all cancers, the company points out....."cont'd
The study was funded in part by a grant from Pathwork Diagnostics.
Clin Chim Acta. 2011;412:1462–1464. Abstract
(adverse event) abstract: Inadvertent cystotomy at laparoscopic hysterectomy – Sydney West Advanced Pelvic Surgery (SWAPS)
Conclusion:
Inadvertent cystotomy is a recognised complication at hysterectomy. The rate in the SWAPS unit is comparable to that of other published series. Overall, there has been a decline in the rate of bladder injury, which appears attributable to more experience gained with an acquisition of increased skill levels and improved techniques.
Predictive Factors in Relapsed Ovarian Cancer for Complete Tumor Resection
"Results:
Overall, 177 consecutive patients (pts) were analyzed. The median age at first diagnosis was 55 years (range, 23-83 years). The complete tumor resection rate was 44.6%. Predictive factors that correlated with an adverse surgical outcome in terms of residual tumor were ascites <500 ml (Odds ratio, OR=0.3; 95% Confidence interval, CI=0.1-0.8 p<0.05), tumor involvement of the small bowel (OR=0.22; 95% CI=0.07-0.71 p<0.05), tumor spread in the upper abdomen (OR=0.33; 95% CI=0.1-0.9 p<0.05) and platinum resistance (OR=0.1, 95% CI=0.06-0.5 p<0.01).
Serous tumor histology (OR=5.8) appeared to have a protective effect. Age and initial FIGO stage were of no predictive significance.
Conclusion:
Platinum-sensitive patients without ascites, no intestinal tumor involvement, tumor restricted to middle and lower abdomen, and of serous papillary histology have significantly higher complete tumor resection rates. Prospective studies are warranted to evaluate the predictive value of these factors."
The Numbers Game: The Risky Business of Projecting Risk (response/reference breast cancer paper)
Note: worth paying attention to the stats
full free access: Individualized Cost-Effectiveness Analysis
Summary Points
Cost-effectiveness analyses typically express their principal results as incremental cost-effectiveness ratios (ICERs).
ICERs are useful in making decisions for allocation of resources at a population level, but typical ICER measures have shortcomings when used for individual decisions.
For the same ICER, the cost-effectiveness may vary among individuals because not everyone assigns the same priorities to specific outcomes, shares the same attitudes toward risk, or faces the same distribution of expected outcomes.
ICER information can be enhanced by providing additional metrics that individualize cost-effectiveness analyses.
These metrics include the per person net benefit and cost, subgroup ICER estimates for observed measured sources of heterogeneity, and distributions of outcomes and costs for unknown or unmeasured sources of heterogeneity.
Thursday, July 21, 2011
free full access - online presentations - e Health 2011
Note: numerous presentations eg. patient consent, e-records....
Wednesday, July 20, 2011
Monday, July 18, 2011
Risk for CRC in Lynch Syndrome May Be Lower Than We Thought: Prevalence of Alterations in DNA Mismatch Repair Genes in Patients With Young-Onset Colorectal Cancer - Medscape Oncology
"Clearly, as we develop more accurate estimates of risks associated with specific mutations, personalized screening methods and intervals will need to be further clarified among those with LS. Although it appears that the overall risk for CRC among those with LS may be lower than previously thought, there are likely to be specific mutations that confer a higher risk and require more intensive screening protocols."
European Journal of Cancer : Primary versus secondary cytoreduction for epithelial ovarian cancer: A paired analysis of tumour pattern and surgical outcome
Conclusions Secondary cytoreduction due to EOC appears to be associated with significantly lower optimal tumour debulking rates compared to primary setting, since the disease tends to recur in patterns less accessible to complete resection such as gastrointestinal serosa, mesentery and upper abdomen. By maximal surgical effort, tumour residuals significantly correlate between primary and secondary cytoreduction. No other predictors of surgical outcome or tumour-pattern could be identified.
Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells-abstract
"5-Fluorouracil (5-FU) and 5-fluorodeoxyuridine (FdUrd, floxuridine) have activity in multiple tumors, and both agents undergo intracellular processing to active metabolites that disrupt RNA and DNA metabolism." "These findings underscore differences in the cytotoxic mechanisms of 5-FU and FdUrd and suggest that combining FdUrd and PARP inhibitors may be an innovative therapeutic strategy for ovarian tumors."
abstract - Journal of the Neurological Sciences : Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration
second link (further information): "Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. Paraneoplastic cerebellar degeneration is an uncommon disorder that can be associated with any cancer; the most commonly associated are lung cancer (particularly small cell lung cancer (SCLC)), gynecologic and breast cancer, and lymphoma (particularly Hodgkin disease) [1]. The neurologic symptoms frequently precede the diagnosis of cancer, sometimes by an interval of years....."cont'd
Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial
RESULTS:
CA 125 levels were elevated (≥35 U/mL) in 61.5% of 65 patients who had CA 125 data available from samples that were collected <12 months before cancer diagnosis; however, levels of the additional 7 biomarkers were not different between cases and the 3 control groups individually or combined. Two panels that combined CA 125 and the 7 biomarkers failed to improve the sensitivity of CA 125 alone.
CONCLUSIONS:
In contrast to earlier findings from analyzes of postdiagnostically collected sera, the addition of 7 biomarkers to CA 125 did not improve sensitivity for preclinical diagnosis beyond CA 125 alone.Friday, July 15, 2011
Wednesday, July 13, 2011
abstract: Antibiotic use and risk of gynecological cancers (Saskatchewan database)
OBJECTIVES: Several studies addressed the association between antibiotic use and breast cancer risk. The objective of this study was to assess the association between antibiotic use and risk of cervical, ovarian, and uterine cancer.
Video Guide: How to Use the NCI Clinical Trials Search Form - National Cancer Institute
Video Guide: How to Use the NCI Clinical Trials Search Form
The NCI Clinical Trials Search Form allows you to search a list of more than 8,000 clinical trials now accepting participants. The list includes trials supported by NCI, pharmaceutical companies, academic institutions, and other research organizations. The following two videos show users how to use the form and review the results. For additional guidance, see
Help Using the NCI Clinical Trials Search Form.
(Opinion) Letter of Response: Cancer Test Failure - NYTimes.com (“How Bright Promise in Cancer Testing Fell Apart” )
Letter
Cancer Test Failure
Published: July 12, 2011
To the Editor:
Re “How Bright Promise in Cancer Testing Fell Apart” (front page, July 8):
full free access: Nonpulmonary Outcomes of Asbestos Exposure
" The strongest evidence for reproductive disease due to asbestos is in regard to ovarian cancer. Unfortunately, effects on fertility and the developing fetus are under-studied. The possibility of other asbestos-induced health effects does exist. These include brain-related tumors, blood disorders due to the mutagenic and hemolytic properties of asbestos, and peritoneal fibrosis. It is clear from the literature that the adverse properties of asbestos are not confined to the pulmonary system."
Cochrane review: Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma.
OBJECTIVES:
To assess the effectiveness and toxicity of short versus long infusions of paclitaxel for any advanced adenocarcinoma."Adverse events were not comprehensively reported for any of the other comparisons. Outcomes were incompletely documented and QoL outcomes were not reported in any of the trials. The strength of the evidence is weak in this review as it is based on meta analyses of very few trials or single trial analyses and all trials were at moderate risk of bias and two were published in abstract form only."
abstract: A comparison of international breast cancer guidelines - Do the national guidelines differ in treatment recommendations? USA, Canada, Australia, the UK, and Germany
(USA, Canada, Australia, the UK, and Germany)
CONCLUDING STATEMENT: Considering that the development of guidelines is a very expensive and resource-intensive task the question arises whether the development of national guidelines in numerous countries is worth the effort since the recommendations differ only marginally.
abstract: The association between endometriosis and gynecological cancers and breast cancer: A review of epidemiological data
CONCLUSIONS:
Endometriosis seems to be a precursor of epithelial ovarian cancer, especially clear cell and endometrioid adenocarcinomas. However, current evidence is insufficient to draw any definitive conclusions whether this association represents causality or the sharing of similar risk factors and/or antecedent mechanismsClostridium Difficile Infection Research - Mayo Clinic
Clostridium Difficile Infection
Research
Mayo researchers have studied the effect of a medicine that binds to the C. difficile toxin so that the toxin does not harm the colon. Another study compared a new antibiotic to vancomycin.Mayo Publications
See a list of publications by Mayo Clinic authors about C. difficile on PubMed, a service of the National Library of Medicine.Monday, July 11, 2011
ongoing media stories - Three more die in C. difficile outbreak - The Globe and Mail
Note:
irrespective of location, C. difficile is an ongoing and unresolved issue (both hospital/non-hospital acquired) and in particular for cancer patients;
it seems the SARS cases of the past have not impacted the 'lessons-not-learned' category and yet people continue to die due to lapses in policy amongst other issues/concerns, patient safety efforts (eg. handwashing...) still need to be addressed (obviously)
abstract - Cancer Letters : Ovarian Clear Cell Carcinoma as a Stress-Responsive Cancer: Influence of the Microenvironment on the Carcinogenesis and Cancer Phenotype
Highlights
► Ovarian endometriosis is known to transform into ovarian cancer, but its etiology is not clarified.
► A stressful microenvironment within the endometriotic cyst may lead to cancer development.
► Ovarian clear cell carcinoma has unique gene expressions, which may serve as a molecular marker.
► Carcinogenic microenvironment affects the phenotype, character and gene expression of a cancer.
► We might be able to develop new treatment based on the analysis of the influence of microenvironment.
Targeting Src in Mucinous Ovarian Carcinoma (dasatinib/oxaliplatin)
"Targeting src kinase with combination of dasatinib and oxaliplatin may be an attractive approach in this disease."
ICGC Releases New Genomic Data on Cancer Ahead of Schedule -- TORONTO, July 11, 2011 /PRNewswire/ --
"...The data include new submissions to the ICGC from The Cancer Genome Atlas (TCGA) in the United States, which has contributed information on about 10 types of cancer affecting the blood, brain, colon, kidney, lung, ovaries, rectum, and uterus, including data from a study of 500 ovarian cancer patients published in the journal Nature on June 30......
Friday, July 08, 2011
Thursday, July 07, 2011
Full text: The relative risk of second primary cancers: a retrospective cohort study
"Within the female cohort, the relative risk of a second cancer was higher for those diagnosed with head and neck cancer, colorectal cancer, lung cancer, melanoma, breast cancer, cervical cancer, uterine cancer, kidney cancer, bladder cancer, thyroid cancer, non-Hodgkin lymphoma, lymphoid leukaemia or myeloid leukaemia.
There were no types of cancer for which female survivors had a significantly lower risk of developing a second invasive cancer (see references to male cancers and lower risk) in relation to the general population."
Table 4. Relative risk of second primary cancer by type of first primary cancer and time period of first diagnosis, Queensland, 1982-2006
repost (abstract) - Gynecologic Oncology : Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors
Research highlights
► Lynch syndrome-associated
ovarian cancer
develops at early age (mean 48 years) with half of the tumors diagnosed at early stage and an overrepresentation of endometrioid (35%) and clear cell (17%) histologies.► MMR gene mutations affect MSH2 in 49%, MSH6 in 33% and MLH1 in 17% with immunohistochemical loss of MMR protein staining in 92%
Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? : : An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
Conclusion
This audit of
ovarian cancer pathology reports reveals that in a substantial number of reports basic pathologic data are missing, with possible adverse consequences for the quality of cancer care. Specialisation by pathologists and the use of standardised synoptic reports can lead to improved quality of reporting. Further research is needed to better define pre- and post-operative diagnostic criteria for ovarian cancer treated with neoadjuvant chemotherapy.
美洲華人生物科學學會 第十三屆國際學術研討會 - conference - Society of Chinese Bioscientists in America
Note: conference agenda online; appears to be some exceptionally interesting presentations
Wednesday, July 06, 2011
Cancer, Fraud, and Bad Biotech! (from former science student....)
Note: see blog's comment section (right hand sidebar - scroll down) and therefore this link
excerpt from website:
FRAUD IS STILL FRAUD AND NO EXCUSE TO STEAL RESEARCH FROM THE PUBLIC!
This is Everyone's Opportunity to Hold Corrupt Businessmen Accountable and Help Make Society Better.
Dear Reader, when I first started this journey I was a student who believed I could contribute to society by discovering science of medical value. I did just that , but to my complete amazement I found myself in trouble with corrupt people...........cont'd
abstract: Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
CONCLUSION: Sorafenib fails to achieve sufficient objective response or sustained disease stabilization as third-line treatment for EOC.
Cancer Society spends more on fundraising than research - Canada - CBC News
Note: consolidated statement
"An Ontario cancer researcher is concerned that the Canadian Cancer Society has proportionally shifted funding away from research and is spending more of its dollars on fundraising and administration costs.
"Most scientists don’t realize that the budget has been going up and up, and donations have been growing, but the budget for research has been shrinking," said Brian Lichty, a researcher at McMaster University who is looking into treating cancer with viruses that kill tumours. "So they are surprised and disappointed when they find out that this is the case, and the trend."
CBC's Marketplace analyzed the Canadian Cancer Society’s financial reports dating back a dozen years. It discovered that each year, as the society raised more dollars, the proportion of money it spent on research dropped dramatically — from 40.3 per cent in 2000 to under 22 per cent in 2011.........."But when Marketplace scrutinized the financial reports, it found that a greater percentage of funds was not being directed toward support, information and advocacy.........cont'd
Monday, July 04, 2011
Subscribe to:
Posts
(
Atom
)
